Home Research

Research

At Icon, we are committed to investing in research and clinical trials, helping to improve cancer treatments and techniques for people now and in the future.

Overview

As Singapore’s only private provider delivering cancer clinical trials, Icon is dedicated to providing more access to research and clinical trials to patients across Singapore. We are part of Icon Group, Australia’s largest dedicated provider of cancer care and private cancer clinical trials program. As a group, we have continued to invest in clinical trials and have played an integral part in the development of new and emerging treatments across haematology, medical oncology and radiation oncology.

Through leveraging our international depth of experience and network of clinicians, we can continue to support our patients through their treatment and offer them opportunities across a range of national and international clinical trials. We want to ensure that you and your loved ones are well informed and have access to advances in treatments and up-to-date research.

Clinical trials provide hope, access and opportunity for cancer patients and help us improve cancer care for people now and into the future by contributing to breakthroughs and advancements to the ways we can treat cancers.

Phases of clinical trials

New treatments are typically tested and developed in four different phases. Icon primarily specialises in Phase I to Phase III clinical trials, and also participates in Phase IV trials and registries across our international network.

If you’re interested in participating in a clinical trial or would like to know more about cancer research, ask your doctor about a clinical trial that could be right for you.

Current clinical trials at Icon Group

You can find Icon’s active clinical trials which are either open or about to open for accrual listed below, including links to the relevant clinical trial registry entries.

To see all publicly and privately supported clinical trials being conducted in Singapore, visit hsa.gov.sg

For a list of trials available at Icon’s Australian centres please click here.

Filters:

Breast Cancer

LEEOMIC: CompLEEment-1 Canadian Correlative Sub-Study Comprehensive Proteomic Analysis Towards Discovery of Predictive Patterns of Protein Expression to Ribociclib Sensitivity and Resistance

RIGHT Choice A Phase II Randomized Study of the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Physician Choice Chemotherapy in Premenopausal or Perimenopausal Patients With Hormone Receptor-positive/ HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer

BYLieve: A Phase II, Multicenter, Open-label, Three-cohort, Non- Comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After Prior Treatments

Liver Cancer

COSMIC-312 A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy

CheckMate 74W A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination With Trans-arterial ChemoEmbolization (TACE) in Patients With Intermediate-stage Hepatocellular Carcinoma (HCC)

Lung Cancer

MS200095-0031 A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)

Chronic Lymphocytic Leukaemia

ACE-CL-309 A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator's Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects With R/R Chronic Lymphocytic Leukemia

Lymphoma

REGENERON_R1979-ONC-1625 A Phase 1 Study to Assess Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, and REGN2810, an Anti-Programmed Death-1 Monoclonal Antibody, in Patients With B-Cell Malignancies

How to participate in a clinical trial

If you are interested in finding out more information on participating in a clinical trial, please speak with your doctor to understand what may be available and appropriate for you and your cancer.